. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: J Neural Transm (Vienna). 2017 Jul 19;124(10):1205–1212. doi: 10.1007/s00702-017-1761-4

Table 1.

Summary of the clinical, cognitive, duration of mentally stimulating activities, motor and PET imaging findings in the study population (n=41). Abbreviations: dihydrotetrabenazine, DTBZ; Mini-mental state examination, MMSE; Movement Disorders Society Revised Unified Parkinson’s Disease Rating Scale, MDS-UPDRS; piperidinyl propionate, PMP; VMAT2, vesicular monoamine transporter type 2.

	Mean value (standard deviation/range)
Age (yr)	68.5±7.2 (56–84)
Gender (male/female)	33/8
Duration of motor disease (yr)	8.1±3.9 (2.5–20)
Time spent in mentally stimulating activities over 4-week period (hr)	20.0±8.3 (2–39)
MMSE	28.4±1.9 (22–30)
Education (yr)	15.4±2.6 (12–20)
Hoehn & Yahr stage	2.6±0.6 (1–5)
MDS-UPDRS part III (motor) score	30.0±10.6 (7–53)
Dorsal caudate nucleus [¹¹C]DTBZ VMAT2 distribution volume ratio	1.83±0.41 (range 1.30–3.4)
Cortical [¹¹C]PMP acetylcholinesterase hydrolysis rate	0.0228±0.0034 (range 0.0175–0.0300) min⁻¹